Incyte’s frontMIND data put pressure on decades-old R-CHOP dominance in high-risk DLBCL
Find out how Incyte’s tafasitamab data could reshape first-line treatment expectations in high-risk DLBCL.
Incyte’s tafasitamab clears pivotal trial in high-risk DLBCL—will it shift front-line treatment?
Incyte Corporation has announced positive topline results from its Phase 3 frontMIND trial evaluating tafasitamab (marketed as Monjuvi/Minjuvi) and lenalidomide in combination with R-CHOP in newly diagnosed diffuse large B-cell lymphoma (DLBCL). The study met its primary endpoint of progression-free survival (PFS) and a key secondary endpoint of event-free survival (EFS), setting the stage for […]